Suven Pharmaceuticals, an integrated contract development and manufacturing organization (CDMO) serving customers worldwide, has been renamed as Cohance Lifesciences.

The Ministry of Corporate Affairs, Government of India (MCA), has given its nod to the change of name from Suven Pharmaceuticals to Cohance Lifesciences with effect from May 7, 2025. The change of the name has been carried out pursuant to the Scheme of Amalgamation.

The Cohance name captures the organization’s commitment to collaborate with global innovators to enhance their molecules and products to deliver transformative solutions to patients and consumers worldwide.  

Commenting on the development, Vivek Sharma, Executive Chairman, Cohance said, “The transition to Cohance Lifesciences marks a pivotal moment in our commitment to better serve our customers and their end market. We are building a global CDMO that aims to enable innovation across a broad range of modalities, chemistries, and technologies, to advance solutions for a healthier world.”.

The company in a statement further added that it would make the necessary application to the BSE and the NSE for effecting the change of name of the company in due course. “We further inform you that the Name Clause of the Memorandum of Association of the Company stands altered accordingly, and the name ‘Suven Pharmaceuticals’ wherever it appears in the Memorandum of Association and the Articles of Association, gets replaced with the new name Cohance Lifesciences,” it added.